Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry Goes On Offensive Against Prescription Pseudoephedrine Trend

This article was originally published in The Tan Sheet

Executive Summary

Drug firms hope to dissuade states from moving drugs that contain methamphetamine precursors to prescription status by funding electronic systems to track nonprescription sales of the products

You may also be interested in...



Electronic Tracking Success Could End Rx-Only Pseudoephedrine In Mississippi

Former Mississippi Gov. Haley Barbour says industry should ask state legislators to repeal the 2010 law that made all PSE drugs Rx-only. CHPA “might get some listeners” if it highlights how the tracking system places less of a financial burden on consumers and the health care system, he says.

Electronic Tracking Success Could End Rx-Only Pseudoephedrine In Mississippi

Former Mississippi Gov. Haley Barbour says industry should ask state legislators to repeal the 2010 law that made all PSE drugs Rx-only. CHPA “might get some listeners” if it highlights how the tracking system places less of a financial burden on consumers and the health care system, he says.

Tennessee Emerges As PSE Battleground With Rx, NPLEx Proposals

The conflict between electronic tracking of pseudoephedrine purchases and shifting the drug ingredient to prescription-only status is elevated in Tennessee as lawmakers offer bills for both anti-methamphetamine strategies.

Related Content

Topics

UsernamePublicRestriction

Register

PS103461

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel